

# Coordination of fracture liaison services (FLS) with primary care in Spain: development of a best practice framework

Prieto-Alhambra D<sup>1</sup>, Naranjo A<sup>2</sup>, Ojeda S<sup>2</sup>, Giner M<sup>3</sup>, Canals L<sup>4</sup>, Balcells-Oliver M<sup>4</sup>, Cancio JM<sup>5</sup>, Duaso E<sup>6</sup>, Mora-Fernández J<sup>7</sup>, Pablos C<sup>8</sup>, González A<sup>8</sup>, Lladó B<sup>9</sup>, Olmo FJ<sup>10</sup>, Montoya MJ<sup>10</sup>, Menéndez A<sup>11</sup>.

1. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK; 2. Department of Rheumatology, Doctor Negrin University Hospital, Las Palmas de Gran Canaria, Spain; 3. Bone Metabolism Unit, Department of Internal Medicine, "Virgen Macarena" University Hospital, Seville, Spain; 4. Amgen, Barcelona; 5. Geriatrics Service, Centre Sociosanitari El Carme, Badalona Serveis Assistencials (BSA), Barcelona, Spain; 6. Geriatrics Service, Igualada Hospital, Barcelona, Spain; 7. Geriatrics Service, Coordinator FLS Hospital Clínico San Carlos, Madrid, Spain; 8. Geriatrics Service, Complejo Asistencial Universitario Salamanca, Salamanca, Spain; 9. Fracture liaison Service, Hospital Son Llatzer, Mallorca, Spain; 10. Fracture liaison Service, "Virgen Macarena" University Hospital, Seville, Spain; 11. Fracture liaison Service, Hospital Vital Álvarez-Buylla, Asturias, Spain.



## INTRODUCTION


- Fracture Liaison Services (FLS) are specific units for secondary fracture prevention and management of osteoporotic (OP) patients<sup>1,2</sup>.
- Effective coordination between FLS and Primary Care (PC) is necessary to ensure long-term care continuity in patients with fragility fractures<sup>2</sup>.

## OBJECTIVE

- To develop a best practice framework for the coordination of FLS with PC in Spain.

## METHODS

**Figure:** A best practice framework for effective FLS-PC coordination was developed in 5 steps



SEIOMM: Spanish Society for Bone and Mineral Research

## RESULTS

**Table:** Proposed standards and performance indicators for FLS-PC coordination

Standard	Performance indicators	Standard	Performance indicators
<b>1. Promotion of FLS-PC communication</b> <ul style="list-style-type: none"> <li>• Regular visits of the champion to PC.</li> <li>• Virtual consultations between FLS-PC.</li> <li>• Email address available for PC.</li> <li>• Quarterly meetings in PC.</li> <li>• Consensus protocols (referral, treatment) developed with PC.</li> <li>• Rotation of PC physicians/nurses in the FLS.</li> <li>• Training sessions in PC.</li> <li>• Promotion of fragility fracture detection in PC.</li> </ul>	<ul style="list-style-type: none"> <li>• Number of consultations (on-site, virtual, e-mail), meetings, protocols, rotations, and training sessions between FLS and PC.</li> <li>• Number of fractures identified in the FLS and percentage received in PC.</li> </ul>	<b>2. Homogenization of fractured patients clinical report content</b> <p>Minimum information to include:</p> <ul style="list-style-type: none"> <li>• General patient data, previous fracture, current fracture, future fracture risk (DXA* and FRAX with DXA), analysis and Spinal x-ray (if performed).</li> <li>• Previous treatment, renal function, comorbidities, other i.e. previous adverse effect, glucocorticoids.</li> <li>• Pharmacological and non-pharmacological recommendations.</li> </ul> <p>Delivery of the clinical report through:</p> <ul style="list-style-type: none"> <li>• Patient.</li> <li>• Medical history.</li> <li>• Internal mail to PC.</li> <li>• Computer platform.</li> </ul>	<ul style="list-style-type: none"> <li>• Number of reports generated by the FLS and percentage received in PC.</li> <li>• Percentage of reports with minimum data.</li> </ul>
<b>3. Treatment adherence</b> <ul style="list-style-type: none"> <li>• Confirmation by the FLS in the first 3 months, by both telephone call and electronic receipt.</li> <li>• Registration in one of the following:                             <ul style="list-style-type: none"> <li>• FLS database.</li> <li>• PC medical history, by PC doctor/nurse.</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Number of patients with treatment initiation and percentage of adherence in the first 3 months</li> <li>• Channels used to assess adherence</li> <li>• Number of phone calls to patients in the first 3 months</li> </ul>	<b>4. Improvement of patient follow-up</b> <ul style="list-style-type: none"> <li>• Setting an automatic appointment with the doctor and the nurse when the FLS report is received in PC.</li> <li>• Educational workshops for patients:                             <ul style="list-style-type: none"> <li>• Development of standard material</li> <li>• Participation of PC physicians and nurses, FLS members, and physiotherapists.</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Number of educational workshops for patients held in PC.</li> </ul>

PC: primary care

## CONCLUSIONS

- Implementation of the recommendations proposed in this best practice framework may improve FLS-PC coordination and thus optimize the follow-up of patients with fragility fracture identified in FLS.
- Performance indicators will allow us to benchmark FLS and to identify improvement strategies.

### Conflicts of interest

Prieto-Alhambra D has received research Grants from Amgen, UCB Biopharma and Les Laboratoires Servier, and non-remunerative positions; the department has received fees for consultancy services from UCB Biopharma and for speaker and advisory board membership services from Amgen. Naranjo A has received research grants from Amgen, consulting fees from UCB and has participated in speakers' bureaus for Amgen and Lilly. Ojeda S has received research grants from Amgen. Mora-Fernández J has received research grants from Amgen and consulting fees from Amgen, Lilly, and UCB-Pharma. Olmo FJ has received consulting fees from Amgen, UCB and Abbott. Giner M, Cancio JM, Duaso E, Montoya MJ and Menéndez A declare no conflict of interests. Canals L and Balcells-Oliver M work at Amgen and hold stock in Amgen.

### Acknowledgements

This study was funded by Amgen S.A. Writing support was provided by Clara Gabás from Outcomes'10.

### References

1. Åkesson K. Osteoporos Int. 2013;24:2135-52.
2. Harvey NCW. Osteoporos Int. 2017;28:1507-29.

